Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Atsushi HiraokaTakashi KumadaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataAtsushi NaganumaHisashi KosakaHiroshi ShibataTomoko AokiTakaaki TanakaHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiYohei KoizumiShinichiro NakamuraKouji JokoHiroko IijimaMasaki KaiboriYoichi HiasaMasatoshi Kudonull nullPublished in: Cancer medicine (2022)
The present study showed that u-HCC patients who received Atez/Bev as a first-line treatment may have a better prognosis than those who received lenvatinib.
Keyphrases